132 related articles for article (PubMed ID: 35307486)
1. Sperm associated antigen 4 promotes SREBP1-mediated de novo lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma.
Liu T; Yu J; Ge C; Zhao F; Chen J; Miao C; Jin W; Zhou Q; Geng Q; Lin H; Tian H; Chen T; Xie H; Cui Y; Yao M; Xiao X; Li J; Li H
Cancer Lett; 2022 Jun; 536():215642. PubMed ID: 35307486
[TBL] [Abstract][Full Text] [Related]
2. DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis.
Feng T; Li S; Zhao G; Li Q; Yuan H; Zhang J; Gu R; Ou D; Guo Y; Kou Q; Wang Q; Li K; Lin P
Cell Oncol (Dordr); 2023 Oct; 46(5):1235-1252. PubMed ID: 37052853
[TBL] [Abstract][Full Text] [Related]
3. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway.
Chen J; Ding C; Chen Y; Hu W; Yu C; Peng C; Feng X; Cheng Q; Wu W; Lu Y; Xie H; Zhou L; Wu J; Zheng S
Cancer Lett; 2021 Apr; 502():154-165. PubMed ID: 33340617
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma-Associated Protein TD26 Interacts and Enhances Sterol Regulatory Element-Binding Protein 1 Activity to Promote Tumor Cell Proliferation and Growth.
Wang C; Tong Y; Wen Y; Cai J; Guo H; Huang L; Xu M; Feng M; Chen X; Zhang J; Wu H; Kong X; Xia Q
Hepatology; 2018 Nov; 68(5):1833-1850. PubMed ID: 29663480
[TBL] [Abstract][Full Text] [Related]
5. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
[TBL] [Abstract][Full Text] [Related]
6. Novel SREBP1 inhibitor cinobufotalin suppresses proliferation of hepatocellular carcinoma by targeting lipogenesis.
Meng H; Shen M; Li J; Zhang R; Li X; Zhao L; Huang G; Liu J
Eur J Pharmacol; 2021 Sep; 906():174280. PubMed ID: 34174265
[TBL] [Abstract][Full Text] [Related]
7. ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p.
Yu X; Lin Q; Wu Z; Zhang Y; Wang T; Zhao S; Song X; Chen C; Wang Z; Xu L; Li C; Gao L; Liang X; Yue X; Ma C
J Pathol; 2020 Dec; 252(4):358-370. PubMed ID: 32770671
[TBL] [Abstract][Full Text] [Related]
8. Suppression of ACADM-Mediated Fatty Acid Oxidation Promotes Hepatocellular Carcinoma via Aberrant CAV1/SREBP1 Signaling.
Ma APY; Yeung CLS; Tey SK; Mao X; Wong SWK; Ng TH; Ko FCF; Kwong EML; Tang AHN; Ng IO; Cai SH; Yun JP; Yam JWP
Cancer Res; 2021 Jul; 81(13):3679-3692. PubMed ID: 33975883
[TBL] [Abstract][Full Text] [Related]
9. Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma.
Bai PS; Xia N; Sun H; Kong Y
J Cell Mol Med; 2017 Nov; 21(11):3023-3043. PubMed ID: 28557334
[TBL] [Abstract][Full Text] [Related]
10. Bufalin Inhibits Tumorigenesis and SREBP-1-Mediated Lipogenesis in Hepatocellular Carcinoma via Modulating the ATP1A1/CA2 Axis.
Huang CJ; Zhang CY; Zhao YK; Wang D; Zhuang L; Qian L; Xie L; Zhu Y; Meng ZQ
Am J Chin Med; 2023; 51(2):461-485. PubMed ID: 36655687
[TBL] [Abstract][Full Text] [Related]
11. Role of hepatoma-derived growth factor in promoting deĀ novo lipogenesis and tumorigenesis in hepatocellular carcinoma.
Min X; Wen J; Zhao L; Wang K; Li Q; Huang G; Liu J; Zhao X
Mol Oncol; 2018 Sep; 12(9):1480-1497. PubMed ID: 30004626
[TBL] [Abstract][Full Text] [Related]
12. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARĪ± pathways.
Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J
J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids
Liu G; Kuang S; Cao R; Wang J; Peng Q; Sun C
FASEB J; 2019 Sep; 33(9):10089-10103. PubMed ID: 31199678
[TBL] [Abstract][Full Text] [Related]
14. Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib.
Liu Y; Sun L; Guo H; Zhou S; Wang C; Ji C; Meng F; Liang S; Zhang B; Yuan Y; Ma K; Li X; Guo X; Cui T; Zhang N; Wang J; Liu Y; Liu L
Oncogene; 2023 Jan; 42(5):374-388. PubMed ID: 36473908
[TBL] [Abstract][Full Text] [Related]
15. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
[TBL] [Abstract][Full Text] [Related]
16. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
Lo AK; Lung RW; Dawson CW; Young LS; Ko CW; Yeung WW; Kang W; To KF; Lo KW
J Pathol; 2018 Oct; 246(2):180-190. PubMed ID: 29968360
[TBL] [Abstract][Full Text] [Related]
17. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
19. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C
J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718
[TBL] [Abstract][Full Text] [Related]
20. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
Wang P; Jiang Z; Liu X; Yu K; Wang C; Li H; Zhong L
Cancer Med; 2020 Oct; 9(19):6972-6983. PubMed ID: 32779397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
